Home Compare AR vs MRNA
Stock Comparison · Structural lead, mixed market

Antero Resources vs Moderna: Which Stock Looks Stronger in 2026?

Antero Resources holds the cleaner structural position, with valuation as the main driver and stability adding further support. Moderna still has the edge on growth, which keeps the comparison from looking entirely one-sided. In the market, Moderna carries the stronger setup — intact trend against Antero Resources's broken trend. That leaves a split case: the structural lead stays with Antero Resources, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.

Updated 2026-05-17

The lead is spread across valuation and stability, rather than sitting in one isolated gap. The overall score gap is 22 points in favour of Antero Resources Corporation.

Trajectory Similarity
0.56
Moderately similar
Peer-set rank: #12
within Antero Resources Corporation's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

The clearest structural overlap shows up in investment intensity and revenue stability.

Similarity drivers
investment intensityrevenue stability
What reduces the match
margin consistency
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
AR
Antero Resources Corporation
58
Peer-Score
Signal qualitylow
Peer basis: Russell 1000
vs
MRNA
Moderna, Inc.
36
Peer-Score
Signal qualitylow
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: AR vs MRNA Profitability 31 13 Stability 38 17 Valuation 83 30 Growth 83 100 AR MRNA
Gap Ranking
#1 Valuation +53
#2 Stability +21
#3 Profitability +18
#4 Growth +17
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AR and MRNA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ARMRNA Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against Moderna, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) and peer-relative valuation score where available.

Entry today — historical context

Where AR and MRNA each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY AR Elevated · near norm 0th 50th 100th 63 pct gap MRNA Lower · below norm 0th 50th 100th 89th 26th
Today MRNA sits in the lower-middle of its own 5-year history (26th percentile), while AR sits higher in its own history (89th). Within each stock's own 5-year context, MRNA is at a historically more favourable entry position than AR. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Valuation
Antero Resources Corporation ranks near the top of the group on valuation; Moderna, Inc. sits in the weaker half.
Stability
Both sit in the weaker half on stability, with Antero Resources Corporation still coming out ahead.
Valuation — Dominant Gap
AR
83
MRNA
30
Gap+53in favour of AR

The peer-relative valuation gap is very wide, with the stronger side also looking meaningfully cheaper.

What keeps the gap from being one-sided

Moderna still pushes back on growth by a very wide margin, which keeps the read from becoming one-way.

What this means for the comparison

Valuation is the clearest driver of the lead, with stability adding further support — though growth still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the AR vs MRNA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-driven comparisons

Explore how AR and MRNA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.